Ver­tex's stel­lar quar­ter car­ries on with French re­im­burse­ment deal

Ver­tex’s gold­en quar­ter just got brighter. About a month af­ter the US drug­mak­er fi­nal­ly clinched a deal with UK au­thor­i­ties to cov­er its slate of cys­tic fi­bro­sis (CF) drugs fol­low­ing years of pro­tract­ed ne­go­ti­a­tions, the com­pa­ny on Wednes­day se­cured a deal with France for its CF ther­a­py, Orkam­bi.

Af­ter the UK, France has one of the largest CF pop­u­la­tions out­side the Unit­ed States. Achiev­ing French re­im­burse­ment un­locks an ~7000-pa­tient CF pop­u­la­tion, around ~2500-3000 of which will like­ly be el­i­gi­ble to re­ceive (and be re­im­bursed for) Orkam­bi, Stifel’s Paul Mat­teis wrote in a note.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.